Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial.

Deal, Jennifer A, Adele M Goman, Marilyn S Albert, Michelle L Arnold, Sheila Burgard, Theresa Chisolm, David Couper, et al. 2018. “Hearing Treatment for Reducing Cognitive Decline: Design and Methods of the Aging and Cognitive Health Evaluation in Elders Randomized Controlled Trial.”. Alzheimer’s & Dementia (New York, N. Y.) 4: 499-507.

Abstract

INTRODUCTION: Hearing impairment is highly prevalent and independently associated with cognitive decline. The Aging and Cognitive Health Evaluation in Elders study is a multicenter randomized controlled trial to determine efficacy of hearing treatment in reducing cognitive decline in older adults. Clinicaltrials.gov Identifier: NCT03243422.

METHODS: Eight hundred fifty participants without dementia aged 70 to 84 years with mild-to-moderate hearing impairment recruited from four United States field sites and randomized 1:1 to a best-practices hearing intervention or health education control. Primary study outcome is 3-year change in global cognitive function. Secondary outcomes include domain-specific cognitive decline, incident dementia, brain structural changes on magnetic resonance imaging, health-related quality of life, physical and social function, and physical activity.

RESULTS: Trial enrollment began January 4, 2018 and is ongoing.

DISCUSSION: When completed in 2022, Aging and Cognitive Health Evaluation in Elders study should provide definitive evidence of the effect of hearing treatment versus education control on cognitive decline in community-dwelling older adults with mild-to-moderate hearing impairment.

Last updated on 10/16/2024
PubMed